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Background: Clinical responses to EGFR tyrosine kinase inhibitors (TKIs) are restricted to tumors harboring
specific activating mutations and even then, not all tyrosine kinase inhibitors provide clinical benefit. All TKIs
however, effectively inhibit EGFR phosphorylation regardless of the mutation present.
Methods: High-throughput, high-content imaging analysis, western blot, Reversed phase protein arrays, mass
spectrometry and RT-qPCR.
Findings: We show that the addition of TKIs results in a strong and rapid intracellular accumulation of EGFR.
This accumulation mimicked clinical efficacy as it was observed only in the context of the combination of a
TKI-sensitive mutation with a clinically effective (type I) TKI. Intracellular accumulation of EGFR was able to
predict response to gefitinib in a panel of cell-lines with different EGFR mutations. Our assay also predicted
clinical benefit to EGFR TKIs on a cohort of pulmonary adenocarcinoma patients (hazard ratio 0.21, P=0.0004
[Cox proportional hazard model]) and could predict the clinical response in patients harboring rare muta-
tions with unknown TKI-sensitivity. All investigated TKIs, regardless of clinical efficacy, inhibited EGFR phos-
phorylation and downstream pathway activation, irrespective of the mutation present. Intracellular
accumulation of EGFR depended on a continued presence of TKI indicating (type I) TKIs remain associated
with the protein even after its dephosphorylation. Accumulation therefore is likely caused by two consecu-
tive conformational changes, induced by both activating mutation and TKI, that combined block EGFR-mem-
brane recycling.
Interpretation: We report on an assay that mimics the discrepancy between molecular and clinical activity of
EGFR-TKIs, which may allow response prediction in vitro and helps understand the mechanism of effective
inhibitors.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/), Erasmus MC, PO Box 2040,
V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)1. Introduction
The epidermal growth factor receptor (EGFR) gene is a key onco-
gene that is mutated in many different cancer types including glio-
mas, colorectal cancer and pulmonary adenocarcinoma. Tumors
depend on EGFR signaling for their growth and this dependency
makes EGFR an attractive target for therapy. Indeed, many pulmo-
nary adenocarcinoma patients harboring EGFR mutations show
strong clinical response to EGFR tyrosine kinase inhibitors (TKIs)
[14]. Unfortunately, other tumor types that depend on EGFRsignaling, such as glioblastomas (the most common and aggressive
type of primary brain cancer), show no response to EGFR-TKIs [57].
Not all EGFR-mutated pulmonary adenocarcinoma patients bene-
fit from EGFR TKIs: responses are predominantly observed in the con-
text of deletions in exon 19 or missense mutations L858R, G719X and
S768I. Patients with other, less common activating mutations such as
exon 20 insertions show no benefit from EGFR TKIs (see e.g. mycan-
cergenome.org) despite EGFR being effectively dephosphorylated
[810]. Apart from this mutation-specificity, there is also a drug-
specificity of clinical responses: where the type I EGFR-TKIs (erloti-
nib, gefitinib, afatinib, dacomitinib and osimertinib) that bind to the
active conformation have provided clinical benefit to EGFR-mutated
pulmonary adenocarcinoma patients, type 1.5 inhibitors that bind to
the inactive conformation (e.g. lapatinib) do not show any sign of
Research in context
Evidence before this study
Preclinical studies have shown that EGFR-mutated tumors
depend on this protein for their growth and several random-
ized phase III clinical trials demonstrated benefit of EGFR inhib-
itors in patients. These trials also showed that benefit was not
universal for all oncogenic mutations; only specific EGFR-muta-
tions appear to respond. In addition, a phase II clinical trial on
lapatinib failed to meet its primary endpoint demonstrating
not all inhibitors are effective. The molecular activity of inhibi-
tors therefore does not explain its clinical activity.
Sources investigated: Pubmed and mycancergenome.org.
Search terms used: pulmonary adenocarcinoma, glioma, EGFR,
EGFR and inhibitor [lapatinib, erlotinib, gefininib, dacomitinib,
osimertinib] and clinical trial, EGFR and conformation, EGFR
and activating mutation, EGFR and T751-I759delinsATA or
L747-E749del or P848L or E746A. Searches were not limited to
a specific timeframe. No selection was made on reporting clini-
cal activity of rare mutations.
Added value of this study
We here describe and validate an assay that mimics the dis-
crepancy between molecular and clinical activity of EGFR-
inhibitors and demonstrate that this in vitro assay allows
response prediction of individual patients.We show that EGFR-
inhibitors remain associated with the protein, but only in the
context of inhibitor-sensitive mutations and clinically effective
inhibitors, this association results in a block in receptor recy-
cling. These data help understand the mechanism of effective
inhibitors.
Implications of all the available evidence
Our data can aid in the clinical decision making in patients har-
boring novel EGFR mutations. Since we show that sensitivity to
EGFR inhibitors is largely independent of the genetic back-
ground, all patients with sensitive EGFR mutations should
(pending independent validation), regardless of the type of
tumor, be considered for treatment with EGFR-TKIs. The block
in receptor recycling can aid the development of novel EGFR
inhibitors of mutations refractory to the ones currently used in
clinical practice.
2 M. de Wit et al. / EBioMedicine 56 (2020) 102796clinical activity [1012]. This lack of clinical activity is surprising as
both type I and 1.5 inhibitors are highly potent in blocking EGFR
phosphorylation. In summary, clinical responses to EGFR TKIs are
restricted to a limited set of mutations only, and not all TKIs are clini-
cally effective. The molecular mechanisms for this mutation- and
drug-specificity remains unknown.
We here describe a simple in-vitro assay, based on a TKI-induced
intracellular accumulation of EGFR, that can predict which mutation
is sensitive to which TKI. Similar to the responses observed in the
clinic, our assay is both mutation and TKI-specific, and is independent
on the inhibition of EGFR-phosphorylation and downstream pathway
activation. The observed TKI-induced intracellular accumulation is
likely a result of a block in intracellular trafficking due to a continued
association of the TKI with EGFR. Because the intracellular accumula-
tion was observed independent of the genetic background of the cell,
our results suggest that accumulation and associated clinical
responses are almost entirely dictated by the combination of muta-
tion and TKI. When validated in a prospective setting this indepen-
dence argues that all patients with sensitive EGFR mutations should,regardless of the type of tumor, be considered for treatment with
EGFR-TKIs.
2. Methods
2.1. Constructs
EGFR mutation constructs were generated by in-fusion cloning.
The backbone of all constructs were essentially as described [13],
with eGFP cloned in-frame 3’ to the transmembrane domain. This
position was chosen to avoid potential interference with ligand bind-
ing or receptor internalization signaling sites. Constructs were cloned
into a piggybac vector (System Biosciences, Palo Alto, Ca) allowing for
rapid integration using transposase into the host genome. Cell-lines
were obtained from the ATCC (Manassas, Virginia). Cells were plated
in 96 or 384 well plates for further analysis.
2.2. Image analysis
All images were obtained using an Opera Phenix high-through-
put high-content confocal microscope (Perkin Elmer, Hamburg,
Germany). At least 10 images were obtained per well so that an
experiment involving a single construct, 6 conditions (5 inhibi-
tors + control) at 10 different dilutions typically would produce
>600 images per timepoint in which data of »1000 cells were
obtained per condition. Channels were independently excited to
minimize potential spectral overlap. Image analysis was performed
in bulk using Harmony software (Perkin Elmer) using identical set-
tings within each experiment. Experiments described in current
manuscript were performed at least in two independent replicates.
Data was further analysed using R.
2.3. Stainings
EGFR antibody (clone H11, DAKO, Amstelveen, the Netherlands)
and a phospho-specific EGFR antibody (AB32430, anti phospho
Y1068, Abcam, Cambridge, UK) were used at 1:500 dilution for both
western blot and immunohistochemistry. Secondary antibodies used
were Alexafluor 647 goat anti-mouse (A21240, Invitrogen, Bleiswijk,
the Netherlands) and Alexafluor 488 goat anti-rabbit (A11008, Invi-
trogen, Bleiswijk, the Netherlands). Hoechst and WGA were used as
counterstain to visualize nucleus and membranes respectively.
2.4. RT-QPCR
RNA was extracted from cells using the RNeasy mini kit (Qiagen,
Venlo, the Netherlands). RT-QPCR was performed using Taqman
probes (Applied Biosystems, Bleiswijk the Netherlands) according to
the manufacturers’ instructions. Expression levels of cFOS and EGR1
were evaluated relative to POP4 and GAPDH controls.
2.5. Patients
We identified pulmonary adenocarcinoma patients harbouring
EGFR mutations from routine diagnostics within the Erasmus MC. For
patients screened in 2016, no selection was made other than pres-
ence of a mutation in the EGFR gene. The data was further expanded
with patients screened in 2017 and 2018 but not including patients
with exon 19 deletions or the L858R missense mutation (thus select-
ing for rare mutations). Patient data were collected in compliance
with to national and institutional guidelines. We generated con-
structs for these mutations. If multiple mutations were identified, the
prediction of response was made based on the one with highest IC50.
Response predictions were performed with the experimenter blinded
to the clinical outcome. The separation into responders/non-respond-
ers was performed blinded to clinical outcome using a predefined
M. de Wit et al. / EBioMedicine 56 (2020) 102796 3cutoff of 500 nM. This cutoff was chosen prior to the analysis and was
based on maximal concentrations of inhibitor that are achieved in
patients, though there is a large inter patient variability [14]. Progres-
sion free survival was defined as the time to progression to first line
TKI treatment. Patients were censored in case of enduring clinical
response or when lost to follow-up.
2.6. RPPA
All samples were prepared according to the guidelines of the MD
Anderson functional proteomics RPPA core facility, where all RPPA
experiments were subsequently run. Cells were maintained under
normal (serum supplemented) culture conditions and inhibitors or
DMSO were added two hours prior to cell lysis. RPPA experiments
were generated in three experiments, with each experiment per-
formed in a separate week at a different cell-passage number to
ensure complete independence.
3. Results
3.1. Clinically effective TKIs induce an intracellular accumulation of
EGFR
To examine mutation- and TKI-specificity of clinical responses, we
generated eGFP-tagged EGFR mutation constructs, stably expressed
them in HeLa cells and monitored response to inhibitors in-vitro.
When erlotinib was added to cells expressing EGFRL858R, we observed
a striking intracellular accumulation of the protein visible as intracel-
lular EGFR-protein ‘spots’ (dozens per cell and up to thousands per
imaging field, Fig. 1a). Using an automated quantitative imaging anal-
ysis setup, we show that the response was dose dependent, occurred
within 5 min following drug administration and persisted for
>3 days (Fig. 1b/c and supplementary Fig. 1 and supplementary
movie 1). In contrast, erlotinib did not induce the intracellular accu-
mulation in cells expressing EGFR-wildtype or EGFRvIII (a deletion of
exons 2-7, the most common mutation in GBMs, Fig. 1a) but did in
cells expressing a construct containing both the EGFRvIII and L858R
mutation (EGFRL858R_vIII, not shown) demonstrating that the accumu-
lation is mutation dependent. Moreover, the intracellular accumula-
tion was observed in cells expressing EGFRL858R only after the
addition of clinically effective drugs erlotinib, gefitinib, dacomitinib
or osimertinib but not after administration of lapatinib, a type 1.5
inhibitor that does not show clinical efficacy (Fig. 1b/c/d, supplemen-
tary Fig. 1). The intracellular accumulation of EGFR in our assay there-
fore was mutation and TKI-dependent.
Osimertinib is a potent third generation EGFR inhibitor with clini-
cal activity also in tumors harboring the secondary T790M resistance
mutation [3]. Cells expressing a construct harboring this T790M
(EGFRL858R+T790M) secondary resistance mutation no longer
responded to erlotinib or gefitinib in our assay, but strongly induced
intracellular accumulation following addition osimertinib (Fig. 1d).
Cells expressing constructs harboring secondary resistance mutations
therefore only induced intracellular accumulation in response to a
TKI that is clinically effective on this mutation.
HeLa cells were chosen as model for these initial experiments as
they do not depend on EGFR for their growth and neither inhibitors
nor the intracellular accumulation induced death in these cells (not
shown). This simple model system therefore avoids potential con-
founding effects of cell death and associated mechanisms and
focusses on the direct effects inhibitors have on EGFR. Accumulation
was however not specific to HeLa cells as erlotinib, gefitinib and osi-
mertinib but not lapatinib, strongly induced the intracellular accu-
mulation in U87 cells expressing EGFRL858R but not in cells
expressing EGFRvIII or EGFRwt (supplementary Fig. 2). We also cre-
ated stable cell lines in which non-tagged EGFR was expressed from a
bicistronic EGFR-IRES-eGFP vector. Similar to the eGFP-taggedmutation constructs, effective EGFR TKIs erlotinib, gefitinib, dacomiti-
nib and osimertinib, but not lapatinib, led to the intracellular accu-
mulation of EGFR, but only in EGFRL858R-IRES-eGFP expressing cells
and not in EGFRwt-IRES-eGFP expressing cells (Fig. 2ac). These data
confirm our observation that clinically effective EGFR-TKIs result in
the accumulation of intracellular EGFR but only in the context of TKI-
sensitive mutations.
To further evaluate intracellular EGFR accumulation, we used four
different lung cancer cell lines that harbour endogenous EGFR muta-
tions. Although all four lung cancer cell lines tested had relatively high
numbers of EGFR-positive intracellular vesicles at baseline, also in these
cell lines a significant increase in the intracellular accumulation of EGFR
was observed when cells were incubated with clinically effective TKIs
(erlotinib, gefinitnib, dacomitinib and osimertinib) but not by the clini-
cally ineffective TKI lapatinib (Fig. 2d). This increase in lung cancer cell
lines was observed as an increase in the number of EGFR-positive intra-
cellular vesicles and their intensity (n = 5 independent replicates). The
inhibitor-induced intracellular accumulation was only observed in cell
lines harbouring TKI-sensitive mutations (HCC827 and H4006) and not
in cell lines that do not harbour TKI-sensitive mutations (H596 nor
H460). Effective EGFR TKIs therefore lead to the intracellular accumula-
tion of EGFR, also in cells harbouring endogenous EGFRmutations.
3.2. Intracellular accumulation predicts response to gefitinib in cell lines
Because of the correlation of the intracellular accumulation with
responses observed in the clinic, we tested whether intracellular accu-
mulation was able to actually predict response to EGFR TKIs. For this,
we screened the Genomics of Drug Sensitivity in Cancer (GDSC) data-
base that contains drug-sensitivity data in >1000 genomically charac-
terized cell-lines [1517]). We selected 11 cell lines with a known EGFR
mutation (10 different mutations) with documented response to gefiti-
nib. We then generated constructs for all EGFR mutations, stably
expressed them in HeLa cells and screened for inhibitor-induced intra-
cellular accumulation. EGFRL858R, EGFRE746_A750del, EGFRL747_E749del,
EGFRS768I, and EGFRG719S all responded to gefitinib by rapidly inducing
intracellular accumulation of EGFR; none of the other mutation con-
structs showed such accumulation (supplementary Fig. 3). Dose
response analysis indicated that EGFRL858R and EGFRE746_A750del were
highly sensitive to gefitinib (IC50 <20 nM) whereas EGFRL747_E749del,
EGFRS768I and EGFRG719S showed considerably higher IC50 values (156,
625 and 456 nM respectively, Fig. 3).
Comparing ‘gefitinib induced intracellular accumulation in HeLa
cells expressing EGFR-mutation constructs’ with ‘gefitinib sensitivity of
cells endogenously expressing EGFR mutations’ showed that the IC50
value for intracellular accumulation was highly similar to the IC50
value for viability (extracted from the GDSC database, supplementary
table 1) for each of the mutations tested (Fig. 3b). Cell lines that are
highly sensitive to gefitinib also harbored mutations that were highly
sensitive to gefitinib induced intracellular accumulation (EGFRL858R
or EGFRE746_A750del), cell-lines with moderate sensitivity harbored
mutations that were moderately sensitive to gefitinib induced intra-
cellular accumulation (EGFRL747_E749del, EGFRS768I or EGFRG719S) and
cell-lines that are insensitive to gefitinib harbored mutations that do
not show gefitinib induced intracellular accumulation (Fig. 3). Of
note, virtually identical results were obtained using erlotinib in our
assay and lapatinib was unable to induce intracellular accumulation
in any EGFR mutation. Our relatively simple and straightforward
assay therefore was able to predict sensitivity to EGFR TKIs in cell
lines harboring endogenous EGFR mutations.
3.3. Intracellular accumulation predicts response to EGFR TKIs in
pulmonary adenocarcinoma patients
To determine whether intracellular accumulation of EGFR can
predict response to TKIs in patients, we screened all pulmonary
Fig. 1. Clinically effective EGFR TKIs induce a rapid and massive intracellular accumulation of EGFR. (a) Erlotinib treatment of HeLa cells ectopically expressing EGFRL858R results in
its intracellular accumulation. This accumulation is not observed in cells expressing EGFRwt or EGFRvIII. Top panels depict the EGFR signal only (Green); bottom panels is a merge
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Fig. 2. Intracellular accumulation of untagged EGFR and in lung cancer cell lines. (a) erlotinib but not lapatinib induces intracellular accumulation of EGFR in HeLa cells expressing
EGFRL858R-IRES-eGFP. (b) quantification of images in A showing lapatinib induces accumulation only in EGFRL858R-IRES-eGFP expressing cells (lower graph) and not in EGFRwt-
IRES-eGFP expressing cells (top graph). (c) Also the HCC827 lung cancer cell line (containing a TKI sensitive mutation), erlotinib and gefinitnib, but not lapatinib induced intracellular
accumulation of EGFR. Quantification of images shown in c demonstrates that both the number of high-intensity spots (d) and the total number of spots (e) increase following treat-
ment with erlotinib, gefitinib, dacomitinib or osimertinib, and not by lapatinib, but only in cell lines harbouring TKI-sensitive mutations (HCC827 and H4006).
M. de Wit et al. / EBioMedicine 56 (2020) 102796 5adenocarcinoma patients treated in 2016 and 2017 within our
clinic for the presence of EGFR mutations (Table 1). For each
mutation identified in this patient cohort (of which the only
selection criterion was the presence of an EGFR mutation), we
generated EGFR-mutation constructs and stably expressed them
in HeLa cells. In each EGFR mutation we tested the ability of TKIs
to induce intracellular accumulation and, if so, determined the
IC50 value thereof. All experiments were performed using auto-
mated image analysis software and were blinded to clinical out-
come. We then split the dataset into ‘predicted responders’ and
‘predicted non-responders’ using a cutoff of 500 nM for intracel-
lular EGFR accumulation. This cutoff was defined prior to per-
forming the experiments and was based on estimates of theincluding Red: WGA (membrane) and blue: Hoechst (nucleus). (b) intracellular accumulation
tinib but not with lapatinib. The intracellular accumulation is retained up to 60 h (c). (d) Er
resistance mutation EGFRL858R+T790M. They do however remain responsive to osimertinib (
reader is referred to the web version of this article.).intra-tumoral concentration of erlotinib (»200ng/g tumor tissue,
though there is a wide inter-patient and intra-tumoral variability
[14]). On this dataset, we show that ‘predicted responders’ had a
significantly longer time to progression to first line EGFR TKIs
than the ‘predicted non-responders’ (median survival 7.0 vs 13
months, HR 0.21, P=0.0004 [Cox proportional hazard], Fig. 4).
Explorative analysis of other cutoffs points (ranging from
101000 nM) is shown in supplementary Fig. 3b.
It should be noted that some tumors harbored more than one
EGFR mutation, in which case we used the mutation with least ability
for intracellular accumulation to predict treatment response. We
defined this prior to any data analysis. However, data from the double
mutant EGFRL858R_vIII could suggest that the accumulation may beis dose dependent and only occurs with clinically effective inhibitors erlotinib and gefi-
lotinib no longer induces intracellular accumulation in cells ectopically expressing the
bottom panels) (For interpretation of the references to color in this figure legend, the
Table 1
Intracellular accumulation formation predicts response to EGFR TKIs in pulmonary adenocarcinoma patients.
Patient drug mutation 1 mutation 2 IC50 mut 1 (nM) IC50 mut 2 (nM) PFS (m) event response prediction
034 gef DL747_T751 156 11 1 Sens
041 erl L858R 30 15 1 sens
060 erl DE746_A750 7 10 1 sens
086 gef DE746_A750 2.4 70 1 sens
088 erl DE746_A750 7 23 1 sens
158 erl DL747_T751 39 18 1 sens
158 erl DK745_A750 7 13 1 sens
175 erl DK745_A750 7 15 1 sens
183 com DE746_A750 7 7 1 sens
196 erl DL747_P753 7 16 1 sens
208 com G719S S768I 156 1250 9 1 insens
228 erl DE746_A750 7 28 1 sens
294 erl G719A 156 3 0 sens
323 erl L858R 30 12 1 sens
345 erl L858R 30 13 1 sens
450 erl DE746_A750 7 10 1 sens
467 erl DE746_A750 7 12 1 sens
475 erl G719S E709A 156 2500 19 1 insens
554 erl DE746_A750 7 33 1 sens
586 erl G719A 156 4 1 sens
640 erl S768I G724S 1250 2 1 insens
650 erl L730R 10000 2 1 insens
655 erl S752If*11 10000 2 1 insens
700 erl S768I L861Q 1250 625 2 1 insens
715 erl G719S E709A 156 2500 11 1 insens
831 gef DE746_A750 2 3 1 sens
845 erl DL747_T751 S768I 39 1250 10 1 insens
854 gef DL747_A750 2 13 1 sens
932 erl L861Q 625 6 1 insens
949 erl L858R 30 12 1 sens
555 erl P848L 10000 1 1 insens
225 crizo G719C S768I 156 1250 3 1 insens
924 erl S768I 1250 12 1 insens
475 erl G719S E709A 156 2500 18 1 insens
608 erl L861Q 625 1 1 insens
743 erl L861Q 625 8 1 insens
924 erl L858R 30 12 1 sens
890 erl L858R L730R 30 10000 2 1 insens
228 erl DE746_A750 7 25 1 sens
747 erl G719A 156 27 1 sens
502 erl G719S E709K 156 10000 10 1 insens
Erl: Erlotinib; gef: gefitinib; com: combination of erlotinib/gefitinib. Only one TKI was administered at one timepoint but toxicity of the first
TKI led to change in regimen to the second TKI; PFS: progression free survival; sens: senstitive; insens: insenstitive.
Fig. 3. Intracellular accumulation of EGFR formation predicts sensitivity to gefitinib in GDSC cell lines. (a) Examples of dose response analysis of intracellular EGFR accumulation. As
can be seen, cells expressing EGFRE746_A750del have a high sensitivity to accumulate EGFR compared to cells expressing EGFRL747-E749del. No intracellular accumulation is observed in
cells expressing EGFRL858R+T790M. (b) Comparison between the ability of gefitinib to induce intracellular accumulation in HeLa cells (IC50 value for intracellular accumulation) with
the sensitivity to gefitinib in the EGFR-mutated GDSC cell-lines (i.e. the IC50 value for viability, see also supplementary Table 1). Despite differences in the cell-lines and assays
used, we find a high concordance between cell viability and inhibitor-induced EGFR intracellular accumulation.
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Fig. 4. Intracellular accumulation of EGFR predicts response to first line treatment in
pulmonary adenocarcinoma patients. Mutation constructs for all activating mutations
in Table 1 (n=41) were generated and the IC50 value for intracellular accumulation to
various TKIs was determined. Patients were then separated into predicted responders
and non-responders (blinded to clinical outcome using a predefined cutoff of 500 nM,
i.e. a clinically achievable concentration). As can be seen, intracellular accumulation
predicts progression free survival in response to first line TKI treatment in pulmonary
adenocarcinoma patients (P=0.0004 [Cox proportional hazard]).
M. de Wit et al. / EBioMedicine 56 (2020) 102796 7dictated by the most sensitive mutation, unless of course this con-
cerns a secondary resistance mutation. We therefore also performed
a similar analysis but used the mutation with highest ability for intra-
cellular accumulation to predict treatment response. Also in this anal-
ysis ‘predicted responders’ had a significantly longer time to
progression to first line EGFR TKIs than the ‘predicted non-respond-
ers’ (median survival 2.0 vs 12 months, HR 0.14, P<0.0001). These
data demonstrate that intracellular accumulation of EGFR s predictive
for clinical response to first line EGFR TKI.3.4. Predicting response to rare mutations
We further evaluated the intracellular accumulation in mutations
where clinical responses to EGFR TKIs is unknown. Because of the rar-
ity of such mutations, we included DIRECT database queries and pub-
lic domain literature to assess clinical responses (Table 2). The
EGFRT751-I759delinsATA mutation showed strong intracellular accumula-
tion (IC50 for gefitinib and erlotinib of 40 and 10 nM respectively)
and was classified as ‘predicted responder’. A patient with similar
mutation indeed showed a partial response to EGFR TKIs and a pro-
gression free survival of 8 months [18]. The EGFRL747-E749del showed
sufficient strong intracellular accumulation (IC50 for gefitinib and
erlotinib of 156 and 432 nM respectively) to be classified as ‘pre-
dicted responder’. The DIRECT database identified two patients har-
boring such mutations and both showed partial responses to EGFR
TKIs (PFS 6 months in one patient, PFS not reported for the other)
[19]. The EGFRE746A missense mutation did not show any sign intra-
cellular accumulation and was classified as ‘predicted non-
responder’. Two patients have been described harboring a similarTable 2
Response prediction of unknown EGFR mutations
Mutation Response prediction Clini
p.L747_E749del sensitive PR
p.L747_E749del sensitive PR
p.E746X insenstitive SD
p.E746X insenstitive SD
P848L insenstitive
P848L insenstitive SD
p.T751_I759del sensitive PR
PR: partial response; SD: stable disease.mutation and neither patient responded to EGFR TKI treatment (both
had stable disease, no PFS reported) [20,21]. Finally, the EGFRP848L
was found in one of our patients and, as predicted by a lack of intra-
cellular accumulation, this patient did not respond to EGFR TKI treat-
ment. A patient with identical mutation also did not respond to
erlotinib [22]. Therefore, also in these rare mutations with previously
unknown sensitivity to EGFR-TKIs, intracellular EGFR accumulation
highly correlated to the clinical responses in all seven patients. These
results therefore further demonstrate that intracellular accumulation
predicts response to EGFR TKIs.3.5. All EGFR TKIs effectively inhibit EGFR and its pathway
Because of the strong phenotype induced by effective EGFR TKIs,
but only on TKI-sensitive mutations, we explored whether these TKIs
and/or mutations differ with respect to pathway activation and inhi-
bition. Western blot analysis showed that all inhibitors effectively
blocked EGFR phosphorylation in HCC827 cells (that contains an
endogenous EGFRE746-A750del mutation, Fig. 5a). In a cell line contain-
ing the T790M resistance mutation (H1975), only osimertinib
reduced EGFR phosphorylation (supplementary Fig. 4a). Two other
lung cancer cell-lines (H460 and H596, EGFR wt and amplified
respectively), showed no EGFR phosphorylation under normal serum
culture conditions (supplementary Fig. 4a, see also [23,24]). Quantita-
tive image analysis, using pan- and phospho-specific EGFR antibody
stainings, confirmed the efficacy of EGFR-TKIs: In cell lines containing
activating EGFR mutations (HCC827 and HCC4006), EGFR is phos-
phorylated and the addition of all tested TKI effectively inhibited this
phosphorylation (Fig. 5b/c). In cell lines without activating EGFR
mutations (NCI-H460 and H596), EGFR is not phosphorylated and
EGF stimulation resulted in a rapid increase in EGFR phosphorylation
levels. Addition of EGFR TKIs prior to EGF stimulation prevented
EGFR-phosphorylation and the addition of TKIs after EGF stimulation
resulted in a rapid dephosphorylation of EGFR (Fig. 5d/e, supplemen-
tary Fig. 4b). Also in stably transfected HeLa cells, all intracellular
accumulation consisted of dephosphorylated EGFR (supplementary
Fig. 5). All examined TKIs therefore effectively block EGFR phosphor-
ylation and therefore cannot explain the differences in the observed
intracellular accumulation.
We performed reversed phase phosphoprotein arrays (RPPA) to
study whether different TKIs and/or mutations differentially affect
pathway activation. We find that erlotinib and lapatinib are equally
effective in blocking downstream EGFR signaling (Fig. 6ac, supple-
mentary Table 2) irrespective of the type of EGFR mutation present
and irrespective of the inhibitor used: in all three cell lines tested
phosphorylation of AKT (serine 473), mTOR (serine 2448) and P90
(threonine 573) was inhibited by the addition of erlotinib or lapati-
nib. We also did not identify differences in other molecular pathways
interrogated by the RPPA arrays between the two inhibitors. RT-qPCR
further demonstrated that EGFR-TKIs effectively blocked the expres-
sion the immediate early genes EGR1 and cFOS, also irrespective of
EGFR mutation type or inhibitor used [13,25,26] (Fig. 6d).cal response PFS ref
6 Yeh et al., 2013
Yeh et al., 2013
Kalikaki et al., 2010
Pallis et al., 2007
1 this manuscript
4.6 Faehling et al., 2017
8 Schrock et al., 2016
Fig. 5. All investigated TKIs effectively inhibit EGFR phosphorylation. (a) all EGFR TKIs effectively block EGFR phosphorylation on western blot in HCC827 and H4006 cell-lines. (b) imaging
analysis showing effects of EGF stimulation on EGFR (and EGFR phosphorylation) in H460 (left panels) and H596 cells (middle and right panels). In H460 cells, EGF stimulation results in
internalization of the receptor. Co-staining for phospho-EGFR shows a rapid increase in EGFR-phosphorylation, which overlaps with the pan-EGFR signal. Right panels are an inset of the yel-
low square in EGF-stimulated H596 cells, depicting phospho-EGFR staining (top) and pan-EGFR staining (red). (c) Quantification of the phospho-EGFR signal in areas staining for pan-EGFR.
As can be seen, EGF stimulation of H596 cells (top panel) results in a very pronounced increase in phospho-EGFR staining per cell (each dot represents an individual area that stained positive
for EGFR). In cells HCC827 cells (lower panel) that have constitutive active EGFR phosphorylation, gefitinib significantly decreases the phospho-EGFR signal. (D) HCC827 cells stained for EGFR
(red, left panels) and phospho-EGFR (green, right panels). As can be seen, all inhibitors effectively reduce EGFR phosphorylation. (e) quantification of images presented in (d) as presented in
(c) (For interpretation of the references to color in this figure legend, the reader is referred to theweb version of this article.).
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Fig. 6. All investigated TKIs effectively inhibit downstream pathway activation. (ac) Erlotinib (orange bars) and lapatinib (blue bars) inhibit EGFR pathway activation
compared to DMSO control (grey bars). (A) AKT S473; (b) mTOR S2448; (c) P90RSK-T573. Total protein levels of these kinases were not altered (not shown). Data are
averages from three independent replicates. (d) RT-QPCR shows efficacy of inhibitors on EGFR-induced gene expression. Both gefitinib and lapatinib result in a decreased
expression of EGR1 and cFOS. Data are shown as the (increase in) the DDCt value relative to the unstimulated control values for these genes. QPCR are averages obtained
from 4 independent replicates. Data are mean +/- SD.
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ent TKIs differentially affect EGFR protein-protein interactions.
Although some inhibitor-specific protein-protein interactions were
identified across the various cell lines examined ((HCC827, HCC4006
and HeLa cells expressing EGFRL858R, supplementary Table 3), no dif-
ference that was common between erlotinib/gefitinib with lapatinib
was observed. The various TKIs therefore have similar inhibition of
EGFR, its pathways and its interactome and therefore do not provide
an explanation for the TKI- and mutation-specific intracellular accu-
mulation in EGFR.
3.6. A two-step conformational change model may explain the
intracellular accumulation
EGFR is phosphorylated and internalized after its activation by
ligand (see e.g. Fig. 5b and [27]). Once trafficked into earlyendosomes, the protein is eventually dephosphorylated and either
recycled back to the plasma membrane or transported to the lyso-
some for degradation. As activated EGFR remaining in the cytoplasm
will be recycled back to the membrane, it follows that the inhibition
of EGFR activity will result in a (relative) increase in the membrane
fraction of the protein. Indeed, quantification of the membrane/cyto-
plasm ratio of EGFR shows that EGFR-TKIs result in an increased
membrane association in cells expressing EGFRwt (Fig. 7). Interest-
ingly, only lapatinib resulted in this increased membrane association
in cells expressing EGFRL858R; other TKIs resulted in an increased
intracellular accumulation.
We hypothesized that the difference between lapatinib and other
TKIs on EGFRL858R may lie in the differential conformational prefer-
ence of TKIs: erlotinib (a type I inhibitor) associates with the active
conformation while the type 1.5 inhibitor lapatinib traps the protein
in an inactive conformation [2830]. In EGFRwt such conformational
Fig. 7. Lapatinib increased membrane association of EGFR. (a) example of images showing increased membrane association following treatment with lapatinib in cells expressing
EGFRwt or EGFRL858R. (b) Quantification of images shown in a. Data are presented as median and the 25% and 75% interquartile range.
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the protein will adopt an inactive conformation and the protein is
recycled to the membrane. However, specific activating mutations
such as EGFRL858R destabilize (or even are incompatible with-) the
inactive confirmation and promote the protein to adopt its active
conformation [28,29,31]. Since erlotinib associates with the active
conformation it is possible that, in the context of EGFRL858R, the TKI
remains associated with the protein and this association blocks recy-
cling to the plasma membrane.
To demonstrate clinically effective TKIs remain associated with
EGFRL858R, we washed out the various inhibitors and monitored intra-
cellular accumulation. The intracellular accumulation indeed
depended on the continued presence of the inhibitor (despite EGFR
being de-phosphorylated) as removal of competitive inhibitor erlotinib
or osimertinib, but not the non-competitive inhibitor dacomitinib,
resulted in a reversal the intracellular accumulation in HeLa cells
expressing EGFRL858R after >30 min of erlotinib/osimertinib with-
drawal (Fig. 8, supplementary Fig. 6). In lung cancer cell lines harbour-
ing endogenous EGFR mutations, EGFR cannot be re-phosphorylated
even after four hours after washout of the inhibitors further confirm-
ing that TKIs remain associated with EGFR (supplementary Fig. 7).
These results are compatible with the hypothesis that the muta-
tion and TKI-specificity of the intracellular accumulation is be due
to two sequential effects: activating mutations firstly lock the pro-
tein in an active conformation, TKIs that associate with the active
conformation then further affect the conformation of EGFR. Struc-
tural studies confirm that TKIs actively affect the conformation of
EGFR [28,29,31]. This altered conformation then prohibits recycling
to the plasma membrane resulting in an intracellular accumulation
of the protein.
4. Discussion
In this study, we have performed functional analysis on EGFR-
mutation constructs to understand why only specific tumor-typesrespond to EGFR inhibitors, and why only specific inhibitors are clini-
cally effective. We show that the addition of TKIs to cells expressing
EGFR-mutation constructs results in a rapid intracellular accumula-
tion of EGFR, but only on mutations that show clinical response to
EGFR TKIs and only to EGFR-TKIs that are clinically effective. The
accumulation is highly correlated to sensitivity to gefitinib in EGFR-
mutated cell lines, and we show that it predicts response to EGFR-
TKIs in patients.
Our data has two important clinical implications. First of all, our
relatively simple assay can be used to predict the response EGFR TKIs
in tumors harboring mutations where this is not yet known. The
assay can be performed in vitro, and is independent of availability of
patient material: it only requires knowledge on the mutation present.
A large database containing the TKI-induced intracellular accumula-
tion of all possible EGFR-mutations (alone or in combination with
resistance mutations), stably expressed in HeLa cells, would suffice
predicting clinical responses, and to which TKI the mutation is likely
to be most sensitive. Second, since the intracellular accumulation is
seen in cell lines that do not depend on EGFR, our data imply that
response to EGFR-TKIs is almost entirely dictated by the type of
mutation present, and thus is independent of the cell or tumor type.
The tumor type independence of TKI efficacy is supported by several
reports where clinical responses to EGFR TKIs have been observed in
various (non-pulmonary adenocarcinoma) tumor-types harboring
TKI-responsive mutations. In fact, of eight reports found, only one
recurrent thymoma patient harboring an exon 19 deletion (E746-
A705 del) failed to respond to gefitinib; all other patients responded
[3239]. However, the use of ectopic expression however does not
allow screening for intrinsic resistance of cells. Nevertheless, muta-
tion-specificity indicates that all patients with EGFR mutated tumors
(regardless of tumor type), that are sensitive to EGFR-TKIs in lung
cancer, should be considered for treatment with EGFR-TKIs.
It should be noted that we did not observe overt differences
between different TKIs (see e.g. supplementary Fig. 1b) that could be
related to the varying clinical responses (e.g. response duration). It is
Fig. 8. Intracellular accumulation remains dependent on the presence of TKI. With-
drawal of the competitive inhibitor erlotinib (but not the non-competitive inhibitor
dacomitinib) reverts the intracellular accumulation demonstrating dependency on TKI
presence. Such reversion was also observed following withdrawal or competition of
gefitinib and osimertinib (supplementary Fig. 5).
M. de Wit et al. / EBioMedicine 56 (2020) 102796 11therefore possible that clinical efficacy is dictated by the properties of
the inhibitor itself (reversible vs irreversible, IC50, bioavailability) or
by the probability of acquisition of secondary resistance mutations
and/or initiation of other resistance pathways.
Our data also provides some mechanistic insight into how clini-
cally effective EGFR-TKIs may function: they require two sequential
effects on the conformation of the protein. Firstly activating muta-
tions lock the protein in an active conformation. Secondly, TKIs that
associate with the active conformation further affect the conforma-
tion of EGFR which ultimately prohibits the protein recycling to the
plasma membrane. It remains to be determined why the intracellular
accumulation results in effective clinical responses. It is possible that
intracellular accumulation results in an inactivation of all functions of
EGFR, perhaps including those that may not depend on phosphoryla-
tion. Such a ‘TKI-induced sequestering of EGFR’ would explain why
many (non-pulmonary adenocarcinoma) tumors remain dependent
on EGFR for growth, but that inhibition of EGFR-phosphorylation
alone is ineffective [40,41]. If so, targeting EGFR would remain a valid
option for tumors that depend on its signalling for growth.
In summary, we provide an assay that can predict whether a
tumor harboring an unknown mutation will respond to EGFR-TKIs,
and if so, which TKI is most effective. We show that response to
EGFR-TKIs is dictated by the mutation, and not the cell or tumor-
type. If our observations are validated, preferably in a prospectivesetting, it indicates that all patients with sensitive EGFR mutations
should, regardless of the type of tumor, be considered for treatment
with EGFR-TKIs.
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